公开(公告)号：WO0047554A3

公开(公告)日：2001-08-09

申请号：PCT/US0003405

申请日：2000-02-11

Applicant: COR THERAPEUTICS INC

Inventor： SONG YONGHONG ,  ZHU BING-YAN ,  SCARBOROUGH ROBERT M ,  CLIZBE LANE ,  JIA ZHAOZHONG JON ,  SU TING ,  TENG WILLY

IPC: C07D295/14 ,  A61K31/18 ,  A61K31/192 ,  A61K31/195 ,  A61K31/216 ,  A61K31/341 ,  A61K31/40 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/495 ,  A61K31/505 ,  A61K31/517 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P31/04 ,  A61P43/00 ,  C07C257/18 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07D213/56 ,  C07D213/58 ,  C07D213/70 ,  C07D213/74 ,  C07D213/75 ,  C07D217/22 ,  C07D231/12 ,  C07D233/61 ,  C07D239/42 ,  C07D239/94 ,  C07D257/04 ,  C07D295/16 ,  C07D307/54 ,  C07D401/12 ,  C07D521/00 ,  A61K31/16 ,  A61K31/33 ,  C07D231/56

CPC classification number: C07D231/12 ,  C07C311/46 ,  C07C311/51 ,  C07C2601/10 ,  C07D217/22 ,  C07D233/56 ,  C07D239/94 ,  C07D249/08 ,  C07D307/54 ,  C07D401/12

Abstract: Novel compounds of formula in which A is a substituted or unsubstituted phenyl, naphthyl or monocyclic heterocyclic ring, D is a substituted or unsubstituted phenyl or aromatic six-membered heterocyclic ring, K is a substituted or unsubstituted phenyl, naphthyl or bicyclic heterocyclic ring, and the other variables are as defined in the claims, their salts and other derivatives and compositions related thereto having activity against mammalian Factor Xa are disclosed. The coumpounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 其中A是取代或未取代的苯基，萘基或单环杂环的新型式的化合物，D是取代或未取代的苯基或芳族六元杂环，K是取代或未取代的苯基，萘基或双环杂环，以及 其他变量如权利要求中所定义，公开了其与其相关的盐和其它衍生物和组合物具有抗哺乳动物因子Xa的活性。 固体在体外或体内可用于预防或治疗凝血障碍。

公开(公告)号：WO1997014432A1

公开(公告)日：1997-04-24

申请号：PCT/US1996016790

申请日：1996-10-18

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  PHILIPS, David ,  LAW, Debbie, A. ,  ALAIMO, Lisa, N.

IPC: A61K39/00

CPC classification number: C07K14/70546

Abstract: The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the beta -subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of identifying agents which block integrin mediated signaling, methods of using agents which block intergrin mediated signaling to modulate biological and pathological processes, and agents which block integrin mediated signaling.

Abstract translation: 本发明公开了信号蛋白结合所需的β亚单位的胞质酪氨酸残基的磷酸化。 本发明提供识别参与整联蛋白介导的信号传导的信号载体的方法，鉴定阻断整联蛋白介导信号传导的试剂的方法，使用阻断整合蛋白介导的信号传导调节生物和病理过程的试剂的方法，以及阻断整合素介导的信号传导的试剂。

公开(公告)号：WO1997011940A1

公开(公告)日：1997-04-03

申请号：PCT/US1996015703

申请日：1996-09-27

Applicant: ELI LILLY AND COMPANY ,  COR THERAPEUTICS, INC. ,  FISHER, Matthew, J. ,  JAKUBOWSKI, Joseph, A. ,  MASTERS, John, J. ,  MULLANEY, Jeffrey, T. ,  PAAL, Michael ,  RÜHTER, Gerd ,  RUTERBORIES, Kenneth, J. ,  SCARBOROUGH, Robert, M. ,  SCHOTTEN, Theo ,  STENZEL, Wolfgang

Inventor： ELI LILLY AND COMPANY ,  COR THERAPEUTICS, INC.

IPC: C07D221/20

CPC classification number: C07D221/20 ,  A61K31/423 ,  A61K31/437 ,  C07D263/52 ,  C07D471/10

Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Abstract translation: 本发明涉及用碱性和酸性官能团取代的某些螺环化合物，其可用于抑制血小板聚集。

公开(公告)号：WO9502054A3

公开(公告)日：1995-06-08

申请号：PCT/US9407644

申请日：1994-07-07

Applicant: COR THERAPEUTICS INC

Inventor： LANZA FRANCOIS ,  PHILLIPS DAVID R ,  CAZENAVE JEAN-PIERRE

IPC: G01N33/50 ,  A61K38/00 ,  A61K39/395 ,  A61P7/04 ,  C07H21/04 ,  C07K14/705 ,  C07K16/28 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/68 ,  A61K38/16

CPC classification number: C07K14/705 ,  A61K38/00

Abstract: This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with other glycoproteins is described and several uses of the isolated glycoprotein v gene are shown.

公开(公告)号：WO1993010805A1

公开(公告)日：1993-06-10

申请号：PCT/US1992010359

申请日：1992-12-01

Applicant: COR THERAPEUTICS, INC. ,  RAMAKRISHNAN, Vanitha ,  ESCOBEDO, Maria, A. ,  FRETTO, Larry, J.

Inventor： COR THERAPEUTICS, INC.

IPC: A61K37/00

CPC classification number: C07K16/2863 ,  A61K38/00 ,  C07K14/71 ,  C07K2317/34

Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerisation, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

Abstract translation: 本发明涉及特异性结合人β型PDGF受体的细胞外结构域的免疫球蛋白多肽。 免疫球蛋白多肽与受体的结合抑制PDGF诱导（或刺激的）受体活化，如通过受体磷酸化和二聚化的抑制以及通过抑制PDGF介导的有丝分裂，趋化性和显示人PDGF型β受体的细胞的迁移所表明的 在细胞表面。 编码免疫球蛋白多肽的核酸也包括在本发明中。 免疫球蛋白多肽具有诊断和治疗用途。

公开(公告)号：WO1992004378A1

公开(公告)日：1992-03-19

申请号：PCT/US1991006337

申请日：1991-09-04

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  WOLF, David

IPC: C07K13/00

CPC classification number: C12N9/647 ,  A61K38/00 ,  C07K14/745 ,  C12N9/6432 ,  C12Y304/21006

Abstract: Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be conveniently prepared using recombinant techniques. In addition, modified forms of Factor Xa that generate Factor Xa in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of Factor Xa are typically acylated forms of the serine residue in the active site which are slowly deacylated in vivo.

公开(公告)号：WO0217711A9

公开(公告)日：2003-10-30

申请号：PCT/US0126936

申请日：2001-08-31

Applicant: COR THERAPEUTICS INC ,  RAMAKRISHNAN VANITHA ,  PHILLIPS DAVID

Inventor： RAMAKRISHNAN VANITHA ,  PHILLIPS DAVID

IPC: A61P7/00 ,  C07K14/705 ,  C12N15/85 ,  G01N33/569 ,  G01N33/86 ,  A01K67/027

CPC classification number: C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0375 ,  C07K14/705 ,  G01N33/56966 ,  G01N33/86 ,  G01N2333/435 ,  G01N2333/70546 ,  G01N2333/974 ,  G01N2500/10

Abstract: The present invention relates to therapeutics and diagnostics that take advantage of a novel signal transduction pathway in platelets. In addition, the present invention provides methods for identifying agents that modulate activities mediated by the novel transduction pathway including platelet activation and thrombosis.

Abstract translation: 本发明涉及利用血小板中新的信号转导途径的治疗和诊断。 另外，本发明提供了鉴定调节由新转导途径介导的活性的试剂的方法，包括血小板活化和血栓形成。

公开(公告)号：WO0194330A3

公开(公告)日：2002-08-29

申请号：PCT/US0117688

申请日：2001-06-01

Applicant: COR THERAPEUTICS INC ,  KANTER JAMES ,  MULLINS JOHN J G ,  SCARBOROUGH ROBERT ,  WALKER DERRICK ,  HENSE THOMAS

Inventor： KANTER JAMES ,  MULLINS JOHN J G ,  SCARBOROUGH ROBERT ,  WALKER DERRICK ,  HENSE THOMAS

IPC: A61P7/00 ,  C07D311/20 ,  C07D311/22 ,  C07D311/58 ,  C07D311/70 ,  A61K31/35

CPC classification number: C07D311/22 ,  C07D311/20 ,  C07D311/58

Abstract: Disclosed are processes for producing chromane compounds, preferably chroman-2-yl acetic acid compounds and 6-amino-chroman-2-yl acetic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors.

Abstract translation: 本发明公开了生产色氨酸化合物，优选苯并二氢吡喃-2-基乙酸化合物和6-氨基 - 苯并二氢吡喃-2-基乙酸酯的方法，其为制备血小板聚集抑制剂的中间体和/或本身是有效的血小板聚集抑制剂。

公开(公告)号：WO0194335A3

公开(公告)日：2002-08-08

申请号：PCT/US0117980

申请日：2001-06-01

Applicant: LILLY CO ELI ,  COR THERAPEUTICS INC ,  BRIGGS BARBARA ,  HANSEN MARVIN ,  KANTER JAMES ,  MULLINS JOHN J G ,  RUHTER GERD ,  UDODONG UKO ,  VERRAL DANIEL II ,  ZMIJEWSKI MILTON JR

Inventor： BRIGGS BARBARA ,  HANSEN MARVIN ,  KANTER JAMES ,  MULLINS JOHN J G ,  RUHTER GERD ,  UDODONG UKO ,  VERRAL DANIEL II ,  ZMIJEWSKI MILTON JR

IPC: A61K31/353 ,  A61P7/02 ,  C07D311/22 ,  C07D311/24 ,  C07D311/58 ,  C07D311/74 ,  C07D311/70

CPC classification number: C07D311/74 ,  A61K31/353 ,  C07D311/22 ,  C07D311/24 ,  C07D311/58

Abstract: Disclosed are process steps and novel processes for producing chromane compositions enriched in at least one (2R or 2S) enantiomer, preferably chroman-2-yl carboxylic acid compounds and chroman-2-yl carboxylic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors. Further disclosed are enzymatic processes for resolving chiral intermediates or final products to provide desired enantiomers.

Abstract translation: 公开了生产富集至少一种（2R或2S）对映异构体，优选苯并二氢吡喃-2-基羧酸化合物和色满-2-基羧酸酯的色淀组合物的方法步骤和新方法，其是制备血小板聚集抑制剂的中间体， /或本身是有效的血小板聚集抑制剂。 进一步公开的是用于拆分手性中间体或最终产物以提供所需对映异构体的酶法。

公开(公告)号：WO0187871A3

公开(公告)日：2002-04-04

申请号：PCT/US0115687

申请日：2001-05-16

Applicant: COR THERAPEUTICS INC ,  SCARBOROUGH ROBERT ,  KALARITIS PANOS ,  STEENROD J GUY ,  YIANNIKOUROS GEORGE

Inventor： SCARBOROUGH ROBERT ,  KALARITIS PANOS ,  STEENROD J GUY ,  YIANNIKOUROS GEORGE

IPC: C07D311/74 ,  C07D311/06

CPC classification number: C07D311/74

Abstract: Disclosed are processes for producing chromane compounds, preferably 2-(6-aminochroman-2-yl) acetic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors.

Abstract translation: 公开了用于生产色原化合物，优选2-（6-氨基苯并二氢吡喃-2-基）乙酸酯的方法，其是用于产生血小板聚集抑制剂的中间体和/或本身是有效的血小板聚集抑制剂。